DOI: https://doi.org/10.36347/sjams.2026.v14i02.004

Pages: 124-130

Introduction: Cervical cancer remains the second most common cancer among women worldwide and the leading cause of cancer death. Depending on the center and the screening policy in place, primary screening may involve HPV testing, cervical smear testing, or both in a “co-testing” approach. The objective of our study was to describe the results obtained after primary co-testing screening. More specifically, we sought to report the epidemiological profile of patients, describe the cytology results and the results for HPV viruses detected, and correlate the type of HPV virus with the precancerous lesions detected. Materials and methods: This was a retrospective, descriptive, and analytical study involving 99 patients. The parameters studied concerned epidemiological data, cytological aspects of smears, and HPV test results. Performance indicators [sensitivity, specificity, PPV, NPV, accuracy, Youden's index], concordance [Cohen's kappa], and McNemar's test were calculated. The analyses were performed using R. Results: Ninety-nine women were included. The mean age was 44.3 ± 10.2 years. HPV positivity was 24%, dominated by high-risk genotypes [76%]. The prevalence of cytological abnormalities was 8.1%. The HPV test had a sensitivity of 12.5% and a specificity of 74.7%, with a high NPV [90.7%] and low concordance with cytology [kappa = −0.07]. Conclusion: Co-testing shows good exclusion capacity but limited concordance in this context. Standardization of techniques and integration of molecular typing could improve performance.